Catheters and Tools with Pulsed Field Ablation—Pulmonary Vein Isolation and Nanosecond Pulse Field Ablation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F25%3A00010045" target="_blank" >RIV/00023884:_____/25:00010045 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10511095

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/abs/pii/S1877918225000176?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S1877918225000176?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ccep.2025.02.015" target="_blank" >10.1016/j.ccep.2025.02.015</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Catheters and Tools with Pulsed Field Ablation—Pulmonary Vein Isolation and Nanosecond Pulse Field Ablation

Popis výsledku v původním jazyce

Pulse Field Ablation (PFA) has gained attention in the field of atrial fibrillation catheter treatment recently and the initial PFA systems have demonstrated excellent safety and efficacy profiles. All currently used or developed technologies use ultrashort pulses (on the order of microseconds) to create strong electrical field for myocardial tissue ablation. The Emerging CellFX System (Pulse Biosciences, Inc.) utilizes nanosecond PFA (nsPFA), whose pulses last less than a microsecond, typically tens to hundreds of nanoseconds, and are thus several orders of magnitude shorter than the initial PFA systems. There are several potential advantages of nsPFA over microsecond PFA such as deeper penetration of the electric field into tissue, creating larger and deeper ablation zones while depositing less overall energy and heat, faster treatment and less muscle stimulation or nerve capture. The safety and effectivity of nsPFA in cardiac tissue has already been demonstrated in an animal model. Since December 2023, the first in man feasibility clinical trial using nsPFA has been taking place at Na Homolce Hospital in Prague, Czech Republic. 54 patients with paroxysmal atrial fibrillation have already been included in the study. Preliminary experience with CellFX technology performance is encouraging and final results are expected during 2025.

Název v anglickém jazyce

Catheters and Tools with Pulsed Field Ablation—Pulmonary Vein Isolation and Nanosecond Pulse Field Ablation

Popis výsledku anglicky

Pulse Field Ablation (PFA) has gained attention in the field of atrial fibrillation catheter treatment recently and the initial PFA systems have demonstrated excellent safety and efficacy profiles. All currently used or developed technologies use ultrashort pulses (on the order of microseconds) to create strong electrical field for myocardial tissue ablation. The Emerging CellFX System (Pulse Biosciences, Inc.) utilizes nanosecond PFA (nsPFA), whose pulses last less than a microsecond, typically tens to hundreds of nanoseconds, and are thus several orders of magnitude shorter than the initial PFA systems. There are several potential advantages of nsPFA over microsecond PFA such as deeper penetration of the electric field into tissue, creating larger and deeper ablation zones while depositing less overall energy and heat, faster treatment and less muscle stimulation or nerve capture. The safety and effectivity of nsPFA in cardiac tissue has already been demonstrated in an animal model. Since December 2023, the first in man feasibility clinical trial using nsPFA has been taking place at Na Homolce Hospital in Prague, Czech Republic. 54 patients with paroxysmal atrial fibrillation have already been included in the study. Preliminary experience with CellFX technology performance is encouraging and final results are expected during 2025.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cardiac Electrophysiology Clinics

ISSN

1877-9182

e-ISSN

—

Svazek periodika

17

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

273-285

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-105000274411